following an abbreviated submission:
dupilumab (Dupixent®) is accepted for restricted use within NHSScotland.
Indication under review: the treatment of moderate-to-severe atopic dermatitis in adolescents (≥12 to <18 years) who are candidates for systemic therapy.
SMC restriction: patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.
SMC has previously accepted dupilumab for restricted use under the orphan medicine process for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy (SMC2011). This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
Download detailed advice361KB (PDF)
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
For the treatment of moderate-to-severe atopic dermatitis in adult and adolescents 12 years and older who are candidates for systemic therapy
- Pharmaceutical company
- BNF chapter
- Submission type
- Date advice published
- 13 January 2020